tbuckley/cabot-search huggingface dataset:
The Propaganda for Reform
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene “Switch” Stops Colon Cancer in Mice
Journal: Cancer Discovery (2015)

Researchers developed a mouse model that enabled them to alternately silence and reactivate the tumor suppressor gene adenomatous polyposis coli, which is mutated in the majority of human colorectal cancers. When the tumor suppressor gene was reactivated, the tumors completely regressed within 2 weeks, even in the presence of mutations that commonly sustain disease progression.
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Authors: Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, Alastair W.S. Ritchie, Rick Kaplan, Benjamin Smith, Ian D. Davis, Martin R. Stockler, Laurence Albiges, Bernard Escudier, James Larkin, Steven Joniau, Barry Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh K.B. Parmar, Patrick Royston, Angela Meade
Journal: Journal of Clinical Oncology (2022)

The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomized trial of sorafenib after excision of primary RCC.Data used to derive the 2003 Leibovich score were compared with contemporary data from SORCE. Discrimination and calibration of the metastasis-free survival outcome were assessed in data from patients with clear-cell RCC, using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c indexes. Secondary analyses involved three important SORCE groups: patients with any non-clear-cell subtype, papillary, and chromophobe carcinomas.Four hundred seven recurrences occurred in 982 patients in the Leibovich cohort and 520 recurrences were recorded in 1,445 patients in the primary SORCE cohort. Clear discrimination between intermediate-risk and high-risk SORCE cohorts was shown; hazard ratio 2.74 (95% CI, 2.29 to 3.28), c-index 0.63 (95% CI, 0.61 to 0.65). A hazard ratio of 0.61 (95% CI, 0.53 to 0.70) confirmed poor calibration of the two cohorts. Discrimination was observed in secondary populations, with c-indexes of 0.64 (95% CI, 0.59 to 0.69) for non-clear-cell RCC, 0.63 (95% CI, 0.56 to 0.69) for papillary RCC, and 0.65 (95% CI, 0.55 to 0.76) for chromophobe RCC.The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non-clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC.
SPONDYLITIS DEFORMANS
Authors: C. W. Buckley
Journal: BMJ (1931)

SPONDYLITIS DEFORMANS THE BRITIDON 7. Early diagnosis is most important both for the sake of prevention and of cure.Most cases can be diagnosed by careful clinical examination, but a simple total leucocyte count of the blood is of material aid in the differential diagnosis between influenza and the early stages of cerebro-spinal fever.8. The globulin content of the cerebro-spinal fluid and the position of the meningococci, whether chiefly intra- cellular or extracellular, are valuable prognostic guides.
Book Review Organization, Strategy and Tactics of the Army Medical Services in War . By Lieutenant Colonel T. B. Nicholls, M.B., Ch.B. With chapters by Air-Commodore A. S. Glynn, M.B., Ch.B., K.H.S., R.A.F.; Colonel A. R. Laurie, M.B., Ch.B., D.M.R.E. (T.A.); and Colonel F. G. Lescher, Medical Corps, M.A., M.D., M.R.C.P. (T.A.). 8°, cloth, 488 pp. London: Baillière, Tindall and Cox, 1940. Obtainable in the United States from Williams and Wilkins Company. $5.00.
Journal: New England Journal of Medicine (1941)
Correction: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells
Authors: K Vrzalikova, M Ibrahim, M Vockerodt, T Perry, S Margielewska, L Lupino, E Nagy, E Soilleux, D Liebelt, R Hollows, A Last, G Reynolds, M Abdullah, H Curley, M Care, D Krappmann, R Tooze, J Allegood, S Spiegel, W Wei, C B J Woodman, P G Murray
Journal: Leukemia (2019)

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Vascular surgery
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<TITLE>Preventing Dehydration From Diarrhea</TITLE>
Journal: JAMA (2001)

Decreased Skin TurgorSunken Eyes and Cheeks Diarrhea (frequent loose or watery bowel movements) can be caused by bacteria, viruses, or parasites that infect the intestines.Diarrhea can also be caused by intolerance to substances found in some foods or by some medications.Chronic diarrhea (diarrhea that lasts for more than 2 to 3 weeks) can be a symptom of some chronic diseases.An article in the January 17, 2001, issue of JAMA discusses the development of guidelines for testing stool samples for bacterial infection in hospitalized patients.Tests on stool samples can help determine the cause of diarrhea.
Alzheimer-Related Protein Suppresses Gliomas
Journal: Cancer Discovery (2020)

Abstract In low-grade gliomas, mutant forms of IDH1/2 trigger expression of tau, a protein typically associated with neurodegenerative disease that also inhibits EGFR signaling to impede tumor progression. The new findings provide a scientific rationale for pharmacologically mimicking the function of tau with microtubule-stabilizing drugs for the treatment of brain tumors.
Table of Contents
Authors: Robert Hodgson, Michael Kashgarian, Lorraine Racusen, John Feehally, Philip Kalra, Anna Francis, Colin Baigent, T Alp Ikizler, Paul Cockwell, Vivekanand Jha, Ziad Massy, Tilman Drueke, Griffith Perkins, Juewan Kim, P Coates, Andrew Hall, Marcello Polesel, Fabiola Terzi, Lesley Inker, Andrew Levey, Brad Rovin, Maurice Laville, Craig Coorey, Ankit Sharma, Samuel Muller, Jean Yee, Hwa Yang, Hannah Bullock, Cynthia Goldsmith, Sara Miller, Amanda Clark, Samir Parikh
Journal: Kidney International (2021)
Racial Differences in Genomic Profiles of Breast Cancer
Authors: Neha Goel, Daniel Y. Kim, Jimmy A. Guo, Daniel Zhao, Brandon A. Mahal, Mohammed Alshalalfa
Journal: JAMA Network Open (2022)

This genetic association study examines the tumor genomic profiles by race in a large, diverse patient cohort using next-generation sequencing (NGS) data in the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange.
Journal d'Urologie et de Néphrologie, Paris
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The role of key gut microbial metabolites in the development and treatment of cancer
Authors: Kayla Jaye, Chun Guang Li, Dennis Chang, Deep Jyoti Bhuyan
Journal: Gut Microbes (2022)

In recent years, the role of gut microbial metabolites on the inhibition and progression of cancer has gained significant interest in anticancer research. It has been established that the gut microbiome plays a pivotal role in the development, treatment and prognosis of different cancer types which is often mediated through the gut microbial metabolites. For instance, gut microbial metabolites including bacteriocins, short-chain fatty acids and phenylpropanoid-derived metabolites have displayed direct and indirect anticancer activities through different molecular mechanisms. Despite the reported anticancer activity, some gut microbial metabolites including secondary bile acids have exhibited pro-carcinogenic properties. This review draws a critical summary and assessment of the current studies demonstrating the carcinogenic and anticancer activity of gut microbial metabolites and emphasises the need to further investigate the interactions of these metabolites with the immune system as well as the tumour microenvironment in molecular mechanistic and clinical studies.
BOOK REVIEWS
Authors: A. THIBAULT
Journal: JNCI Journal of the National Cancer Institute (1993)

BOOK REVIEWS Get access Cancer of the Prostate Sakti Das , E. David Crawford , eds. New York : Marcel Dekker , 1993 . 462 pp., illus. $135 ISBN 0-8247-8863-x ALAIN THIBAULT, M.D. ALAIN THIBAULT, M.D. Clinical Pharmacology Branch National Cancer Institute National Institutes of Health Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 23, 1 December 1993, Pages 1958–1959, https://doi.org/10.1093/jnci/85.23.1958-a Published: 01 December 1993
Consensus conference. Platelet transfusion therapy
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Preference for Site of Terminal Care
Journal: Annals of Internal Medicine (2000)

Corrections7 March 2000Correction: Preference for Site of Terminal CareFREESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-5-200003070-00021 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In a brief communication on older patients' preference for site of terminal care (1), the first sentence of the first full paragraph on page 110 should read “Of 962 persons screened for participation, 438 [not 1438] did not meet eligibility criteria … .”Reference1. Fried TR, van Doorn C, O'Leary JR, Tinetti ME, Drickamer MA. Older persons' preferences for site of terminal care. Ann Intern Med. 1999;131:109-12. LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOlder Persons' Preferences for Site of Terminal Care Terri R. Fried , Carol van Doorn , John R. O'Leary , Mary E. Tinetti , and Margaret A. Drickamer Metrics 7 March 2000Volume 132, Issue 5Page: 419KeywordsEnd of life care ePublished: 15 August 2000 Issue Published: 7 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Draft Guidance on Remote Data Acquisition in Trials
Authors: Howard D. Larkin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT
Authors: Hong Yao, Wanqun Xie, Yuting Dai, Yanting Liu, Weiting Gu, Jianfeng Li, Liang Wu, Jing Xie, Weiwei Rui, Bohan Ren, Li Xue, Yijun Cheng, Shaojian Lin, Changsheng Li, Hao Tang, Yu Wang, Meiqing Lou, Xiaobiao Zhang, Ronggui Hu, Hanbing Shang, Jinyan Huang, Zhe Bao Wu
Journal: Neuro-Oncology (2022)

Abstract Background Pituitary neuroendocrine tumors (PitNETs) are common intracranial tumors that are classified into seven histological subtypes, including lactotroph, somatotroph, corticotroph, thyrotroph, gonadotroph, null cell, and plurihormonal PitNETs. However, the molecular characteristics of these types of PitNETs are not completely clear. Methods A total of 180 consecutive cases of PitNETs were collected to perform RNA sequencing. All subtypes of PitNETs were distinguished by unsupervised clustering analysis. We investigated the regulation of TPIT by TRIM65 and its effects on ACTH production and secretion in ACTH-secreting pituitary cell lines, as well as in murine models using biochemical analyses, confocal microscopy, and luciferase reporter assays. Results A novel subtype of PitNETs derived from TPIT lineage cells was identified as with normal TPIT transcription but with lowered protein expression. Furthermore, for the first time, TRIM65 was identified as the E3 ubiquitin ligase of TPIT. Depending on the RING domain, TRIM65 ubiquitinated and degraded the TPIT protein at multiple Lys sites. In addition, TRIM65-mediated ubiquitination of TPIT inhibited POMC transcription and ACTH production to determine the fate of the novel subtype of PitNETs in vitro and in vivo. Conclusion Our studies provided a novel classification of PitNETs and revealed that the TRIM65-TPIT complex controlled the fate of the novel subtype of PitNETs, which provides a potential therapy target for Cushing’s disease.
自身免疫性皮肤病的疲乏
Authors: M. Tarazi, R.G. Gaffney, D. Pearson, C.J. Kushner, V.P. Werth
Journal: British Journal of Dermatology (2019)

系统性红斑狼疮(SLE)患者通常出现疲乏,从而降低生活质量和导致健康状况不佳。这项美国宾夕法尼亚和新泽西的研究中作者分析了疲乏是否是其他自身免疫性皮肤病的一个特征。自身免疫是指抗击感染的人体免疫系统实际攻击了健康的细胞。他们使用了36‐项量表(SF‐36),以及特异性活力量表测量对照(无SLE的人)以及SLE、慢性皮肤LE、无肌炎性皮肌炎和自身免疫性大疱病患者的疲乏程度。SLE患者的疲乏程度最差,但所有其他研究疾病都与较对照组更大的疲乏相关。在皮肌炎和大疱病组中疲乏程度相似,但在皮肤LE患者中更小。作者总结,疲乏是这类自身免疫性疾病的一个重要特征,而且对生活质量有不利影响。
<i>Announcement:</i> National Public Health Week — April 3–9, 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

CDC joins the American Public Health Association (APHA) in celebration of National Public Health Week, April 3-9, 2017. Since 1995, APHA has led the observance of National Public Health Week during the first full week of April. The week recognizes the impact of public health on the health of the nation. The 2017 observance focuses on making the United States the Healthiest Nation in One Generation by 2030 by spotlighting the importance of prevention, employing successful strategies for collaboration, and promoting the critical role of a strong public health system.
HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models
Authors: Laetitia Dard, Christophe Hubert, Pauline Esteves, Wendy Blanchard, Ghina Bou About, Lyla Baldasseroni, Elodie Dumon, Chloe Angelini, Mégane Delourme, Véronique Guyonnet-Dupérat, Stéphane Claverol, Laura Fontenille, Karima Kissa, Pierre-Emmanuel Séguéla, Jean-Benoît Thambo, Lévy Nicolas, Yann Herault, Nadège Bellance, Nivea Dias Amoedo, Frédérique Magdinier, Tania Sorg, Didier Lacombe, Rodrigue Rossignol
Journal: Journal of Clinical Investigation (2022)

Germline mutations that activate genes in the canonical RAS/MAPK signaling pathway are responsible for rare human developmental disorders known as RASopathies. Here, we analyzed the molecular determinants of Costello syndrome (CS) using a mouse model expressing HRAS p.G12S, patient skin fibroblasts, hiPSC-derived human cardiomyocytes, a HRAS p.G12V zebrafish model, and human fibroblasts expressing lentiviral constructs carrying HRAS p.G12S or HRAS p.G12A mutations. The findings revealed alteration of mitochondrial proteostasis and defective oxidative phosphorylation in the heart and skeletal muscle of CS mice that were also found in the cell models of the disease. The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics. Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model. Collectively, these findings highlight the importance of mitochondrial proteostasis and bioenergetics in the pathophysiology of RASopathies and suggest that patients with CS may benefit from treatment with mitochondrial modulators.
Reply to Baraldi and Piacentini: Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β<sub>2</sub>-Agonist–Only Treatment
Authors: Liesbeth Duijts, Louise J. Fleming, Leonard B. Bacharier, Paulo M. Pitrez, Helen K. Reddel
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

It has been suggested that desensitization and downregulation of b 2 -receptors, with a loss of bronchodilator response and proinflammatory effects of b 2 -agonists (3), are responsible for the increase in adverse events observed with regular b 2 -agonist treatment.Adding ICS to SABAs improves airway inflammation, enhances b 2 adrenergic receptor expression, and reduces downregulation of b 2 adrenergic receptors (1, 3).In this regard, it has been suggested that regulatory bodies should mandate the use of SABAs alone as off label (4).In the section on the management of asthma in children 5 years and younger, the GINA 2021 recommendation is to "provide inhaled SABA for relief of wheezing episodes."Do we have evidence to indicate that asthma in a 6-year-old is any different from asthma in a child 4-5 years old?To our knowledge, the downregulation of b 2 adrenergic receptors is not age dependent, and eosinophilic airway inflammation occurs in the airways of preschool children with asthma, too (5).Data from several studies show that the prompt use of intermittent high-dose ICS therapy is effective in preventing symptoms from progressing to exacerbation in 35% of cases among preschool-aged children with intermittent asthma or recurrent virally triggered wheezing (6).The GINA working group also warns that starting treatment with SABAs trains parents and patients to regard it as their primary asthma treatment, particularly if training starts in the early years of life.In light of these considerations, we suggest that the GINA recommendation for children .6 years old that low-dose ICS be taken whenever SABAs are taken should apply to preschool-aged children as well.It would be of great interest to pediatricians to have some feedback on this issue from the authors of the GINA 2021 executive summary.
Book Review Preventive Medicine in Modern Practice . Edited under the auspices of the Committee on Public Health Relations of the New York Academy of Medicine. By James A. Miller, Sc.D., M.D., D.P.H.; George Baehr, M.D.; and E. H. L. Corwin, Ph.D. Third edition. 4°, cloth, 851 pp., with 22 illustrations and 37 tables. New York: Paul B. Hoeber, Incorporated, 1942. $10.00.
Journal: New England Journal of Medicine (1943)